Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Janssen's Incivo offers mixed bag of benefits, says IQWiG

This article was originally published in Scrip

Executive Summary

Janssen-Cilag's novel hepatitis C protease inhibitor, Incivo (telaprevir), in combination with peginterferon alfa and ribavirin, potentially offers a “hint” of added benefit for some patients, and more certain benefits for others over current standard therapy (peginterferon alfa and ribavirin), says IQWiG, the German HTA institute. However, it claims that the extent of those benefits is unquantifiable, largely because it does not view sustained virological response (SVR) as a formal patient outcome.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts